These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Sequestering and inhibiting a vascular endothelial growth factor in vivo by systemic administration of a synthetic polymer nanoparticle. Koide H; Yoshimatsu K; Hoshino Y; Ariizumi S; Okishima A; Ide T; Egami H; Hamashima Y; Nishimura Y; Kanazawa H; Miura Y; Asai T; Oku N; Shea KJ J Control Release; 2019 Feb; 295():13-20. PubMed ID: 30578808 [TBL] [Abstract][Full Text] [Related]
3. Design of Functional Nanoparticles for Intractable Disease Therapy. Koide H Biol Pharm Bull; 2021; 44(1):1-6. PubMed ID: 33390535 [TBL] [Abstract][Full Text] [Related]
4. Engineering a vascular endothelial growth factor 165-binding heparan sulfate for vascular therapy. Wang C; Poon S; Murali S; Koo CY; Bell TJ; Hinkley SF; Yeong H; Bhakoo K; Nurcombe V; Cool SM Biomaterials; 2014 Aug; 35(25):6776-86. PubMed ID: 24854095 [TBL] [Abstract][Full Text] [Related]
5. [Design of Synthetic Polymer Nanoparticles That Capture and Neutralize Target Molecules]. Koide H Yakugaku Zasshi; 2021; 141(9):1079-1086. PubMed ID: 34471009 [TBL] [Abstract][Full Text] [Related]
6. Gamabufotalin, a major derivative of bufadienolide, inhibits VEGF-induced angiogenesis by suppressing VEGFR-2 signaling pathway. Tang N; Shi L; Yu Z; Dong P; Wang C; Huo X; Zhang B; Huang S; Deng S; Liu K; Ma T; Wang X; Wu L; Ma XC Oncotarget; 2016 Jan; 7(3):3533-47. PubMed ID: 26657289 [TBL] [Abstract][Full Text] [Related]
7. Binding of Resveratrol to Vascular Endothelial Growth Factor Suppresses Angiogenesis by Inhibiting the Receptor Signaling. Hu WH; Duan R; Xia YT; Xiong QP; Wang HY; Chan GK; Liu SY; Dong TT; Qin QW; Tsim KW J Agric Food Chem; 2019 Jan; 67(4):1127-1137. PubMed ID: 30525561 [TBL] [Abstract][Full Text] [Related]
8. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling. Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875 [TBL] [Abstract][Full Text] [Related]
9. Selective binding of C-6 OH sulfated hyaluronic acid to the angiogenic isoform of VEGF(165). Lim DK; Wylie RG; Langer R; Kohane DS Biomaterials; 2016 Jan; 77():130-138. PubMed ID: 26588795 [TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial cells: Biological effects and advanced glycosilation end products modulation. Pala L; Cresci B; Manuelli C; Maggi E; Yamaguchi YF; Cappugi P; Rotella CM; Giannini S Microvasc Res; 2005 Nov; 70(3):179-88. PubMed ID: 16271941 [TBL] [Abstract][Full Text] [Related]
11. Preparation and cellular targeting study of VEGF-conjugated PLGA nanoparticles. Shi Y; Zhou M; Zhang J; Lu W J Microencapsul; 2015; 32(7):699-704. PubMed ID: 26004370 [TBL] [Abstract][Full Text] [Related]
12. Generation of a chimeric plasmin-resistant VEGF165/VEGF183 (132-158) protein and its comparative activity. Huiyong Z; Yong L; Yunxiao S; Wuling Z; Jingjing L; Taiming L Protein Pept Lett; 2013 Aug; 20(8):947-54. PubMed ID: 23469806 [TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272 [TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling. Huang SW; Lien JC; Kuo SC; Huang TF Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611 [TBL] [Abstract][Full Text] [Related]